AzTrials
AzTrials

Liver DysfunctionPhase 1NCT02005744

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

A Phase 1 study testing CKD-501 in people with Liver Dysfunction, run by Chong Kun Dang Pharmaceutical at 1 site in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function. Read more about this study

Who is it for?
Ages 19 to 64 yearsHealthy volunteers can take part
Conditions the study is for
Liver Dysfunction
What is being tested?
CKD-501
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteSouth Korea
Study dates
Mar 2014to Feb 2016
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 64 years
  • All sexes
  • Healthy volunteers accepted
  • Adult
  1. Inclusion Criteria

[The subjects with impaired hepatic function]

  1. The subjects who are 19 to 64 years old
  2. The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh A or B
  3. Body Weight ≥ 55kg
  4. If females, Negative for pregnancy test at the screening and pre dose of Day 1
  5. The subjects who agreed with performing contraception during the study
  6. The subjects who agreed with written informed consent

[The subjects with normal hepatic function]

  1. The subjects who are 19 to 64 years old
  2. The subjects who are matched impaired hepatic function by gender, age(± 5years) and body weight(± 10kg)
  3. If females, Negative for pregnancy test at the screening and pre dose of Day 1
  4. The subjects who agreed with performing contraception during the study
  5. The subjects who agreed with written informed consent
  6. exclusion criteria

[The subjects with impaired hepatic function]

  1. The subjects with impaired hepatic function as Child-Pugh C
  2. The subjects had a portosystemic shunt surgery
  3. The subjects had a liver transplantation or unsuitable for the study by the investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke, heart failure, cancer etc.) but The subject is eligible to participate if had not chemotherapy or radiofrequency ablation therapy within 6months)
  4. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
  5. The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1
  6. Positive for anti-HIV Ab or venereal disease research laboratory etc.

[The subjects with normal hepatic function]

  1. The subjects with liver disease or abnormal Laboratory test(Asparate transaminase >1.25 fold of upper normal limit, Alanine transaminase>1.25 fold of upper normal limit, Total bilirubin >1.5 fold of upper normal limit)
  2. The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
  3. Estimated Glomerular filtration rate < 60 mL/min/1.73m2 by Modification of Diet in Renal Disease formula
  4. Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease research laboratory
  5. The subjects with high blood pressure or low blood pressure(systolic blood pressure >150mmHg or <100mmHg, diastolic blood pressure>90mmHg or <60mmHg)
  6. The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1 etc.

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Yonsei University Severance Hospital

    Soeul

Other trials in South Korea

About this study

Official title: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Read the detailed description

A Phase 1, Non-randomized, Open, Parallel-Group study.

Being tested
CKD-501
Keywords
CKD-501
Medical subject headings
Liver Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CKD-501Drug

    Also called Lobeglitazone

    CKD-501 0.5mg, PO(per oral), once

Study groups in NCT02005744
Study groupRoleWhat they receive
Child Pugh AExperimentalCKD-501 will be administered to patients who are included Child Pugh A
Receives: Drug: CKD-501
Child Pugh BExperimentalCKD-501 will be administered to patients who are included Child Pugh B
Receives: Drug: CKD-501
Subject who are matched Child Pugh AExperimentalCKD-501 will be administered to the Subjects who are matched Child Pugh A
Receives: Drug: CKD-501
Subject who are matched Child Pugh BExperimentalCKD-501 will be administered to the subjects who are matched Child Pugh B
Receives: Drug: CKD-501

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Area Under the Concentration(last) and Cmax of CKD-501

    Sampling timepoint(hours)

    : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Measured: 0 to 48 hours

Secondary outcomes (4)
  1. Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite

    Sampling timepoint(hours)

    : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Measured: 0 to 48 hours

  2. Fraction Unbound of CKD-501 and its metabolite

    sampling timepoint(hours)

    : 1, 8

    Measured: 1 and 8 hours

  3. Area Under the Concentration(last) and Cmax of the metabolite

    sampling timepoint(hours)

    : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Measured: o to 48 hours

  4. Metabolic ratio(metabolite/CKD-501)

    sampling timepoint(hours)

    : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48

    Measured: 0 to 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2013 (estimated)
  2. Study startMar 2014
  3. Primary completionFeb 2016
  4. Study completionFeb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02005744
Sponsor's protocol ID
19HI13018
Status last verified
May 2014
First submitted
4 Dec 2013
Last updated
4 Jul 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing CKD-501 in people with Liver Dysfunction, run by Chong Kun Dang Pharmaceutical at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Area Under the Concentration(last) and Cmax of CKD-501 (time frame: 0 to 48 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jul 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in